These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Thin-layer chromatographic screening test for polymorphic sparteine oxidation. Ebner T; Meese CO; Eichelbaum M Ther Drug Monit; 1989; 11(2):214-6. PubMed ID: 2718225 [No Abstract] [Full Text] [Related]
8. Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese population. Horai Y; Taga J; Ishizaki T; Ishikawa K Br J Clin Pharmacol; 1990 Jan; 29(1):111-5. PubMed ID: 2297455 [TBL] [Abstract][Full Text] [Related]
9. Sparteine metabolism in a Nigerian population. Ritchie JC; Mitchell SC; Smith RL Drug Metabol Drug Interact; 1996; 13(2):129-35. PubMed ID: 8905244 [TBL] [Abstract][Full Text] [Related]
12. Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities. Eichelbaum M; Bertilsson L; Säwe J; Zekorn C Clin Pharmacol Ther; 1982 Feb; 31(2):184-6. PubMed ID: 7056024 [TBL] [Abstract][Full Text] [Related]
13. Inter-ethnic difference in sparteine oxidation among Ghanaians and Germans. Eichelbaum M; Woolhouse NM Eur J Clin Pharmacol; 1985; 28(1):79-83. PubMed ID: 3987789 [TBL] [Abstract][Full Text] [Related]
14. Evidence for polymorphic oxidation of sparteine in Japanese subjects. Ishizaki T; Eichelbaum M; Horai Y; Hashimoto K; Chiba K; Dengler HJ Br J Clin Pharmacol; 1987 Apr; 23(4):482-5. PubMed ID: 3580254 [TBL] [Abstract][Full Text] [Related]
15. Antipyrine metabolism in relation to polymorphic oxidations of sparteine and debrisoquine. Eichelbaum M; Bertilsson L; Säwe J Br J Clin Pharmacol; 1983 Mar; 15(3):317-21. PubMed ID: 6849767 [TBL] [Abstract][Full Text] [Related]
16. A preliminary note on the transient polymorphic oxidation of sparteine in the Ngawbé Guaymí Amerindians: a case of genetic divergence with tentative phylogenetic time frame for the pathway. Arias TD; Inaba T; Cooke RG; Jorge LF Clin Pharmacol Ther; 1988 Sep; 44(3):343-52. PubMed ID: 3416554 [TBL] [Abstract][Full Text] [Related]
17. Polymorphic oxidation of debrisoquine and sparteine. Eichelbaum M Prog Clin Biol Res; 1986; 214():157-67. PubMed ID: 3523506 [No Abstract] [Full Text] [Related]
18. Quinidine kinetics after a single oral dose in relation to the sparteine oxidation polymorphism in man. Brøsen K; Davidsen F; Gram LF Br J Clin Pharmacol; 1990 Feb; 29(2):248-53. PubMed ID: 2306418 [TBL] [Abstract][Full Text] [Related]
19. Absence of polymorphism of sparteine oxidation in the South African Venda. Sommers DK; Moncrieff J; Avenant JC Hum Exp Toxicol; 1991 May; 10(3):175-8. PubMed ID: 1678945 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism. Sindrup SH; Brøsen K; Gram LF Clin Pharmacol Ther; 1992 Mar; 51(3):288-95. PubMed ID: 1531951 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]